Can spleen surgery shield kidneys in cirrhosis? new study aims to find out

NCT ID NCT07585773

First seen May 18, 2026

Summary

This study follows 30 adults with liver cirrhosis who are having their spleen removed (laparoscopic splenectomy) to treat an enlarged spleen and low blood counts. Researchers will measure kidney function before surgery and for two years after to see if the surgery helps or harms the kidneys. The goal is to better understand how to protect kidney health in people with cirrhosis.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Medical College of Yangzhou University

    Yangzhou, Jiangsu, 225001, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

laparoscopic splenectomy (surgical removal of the spleen)

What this could lead to

If successful, this study could clarify whether removing the spleen helps protect kidney function in cirrhosis patients, potentially guiding future treatment decisions.

What could go wrong

This is a small, observational study (30 people) at a single center, so results may not apply widely. It only measures changes, not proving cause and effect.

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis hypersplenism portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.